Compatibility «Edarbi Klo» and «Enap L Combi»

• Interactions Edarbi Klo with Enap L Combi

  • Dangerous interactions
    • ⓘ Double blockade of RAAS with the use of ARA II, ACE inhibitors or aliskiren (renin inhibitor) is associated with an increased risk of arterial hypotension, syncope, hyperkalemia and renal dysfunction (including acute renal failure) compared with monotherapy.
    • ⓘ In some patients with impaired renal function (for example, in elderly patients or patients with dehydration, including those taking diuretics) receiving NSAID therapy (including selective COX‑2 inhibitors), the simultaneous use of ACE inhibitors or ARA II may cause further deterioration of renal function, including the development of acute renal failure, and hyperkalemia.
    • ⓘ ACE inhibitors (C09A) + angiotensin ii receptor antagonists => Are associated with an increased risk of arterial hypotension, syncope, hyperkalemia and impaired renal function (in pm acute renal failure) compared with monotherapy.
    • ⓘ Thus, patients receiving concomitant digoxin treatment should be monitored for digitalis intoxication.
    • ⓘ Calcium channel blockers(C08) + Drugs that cause hypokalemia; Glucocorticosteroids (C03A, A01AB04,J02AA01,H02,D07 => Increases the likelihood of ventricular tachycardia and ventricular fibrillation. (A dangerous combination, it is necessary to eliminate hypokalemia before use).
    • ⓘ In patients receiving diuretics, especially with the recent appointment of diuretic therapy, there may be an excessive decrease in blood pressure after the start of enalapril.
    • ⓘ In the elderly, patients with hypovolemia (including those receiving diuretics) or impaired renal function, the simultaneous use of enalapril and NSAIDs, including selective COX-2 inhibitors, may lead to deterioration of renal function, including the development of acute renal failure.
    • ⓘ The excessive antihypertensive effect of enalapril can be reduced either by discontinuing the diuretic, or by increasing the BCC or using table salt, as well as by reducing the dose of enalapril.
  • Negative interactions
    • ⓘ Concomitant administration of the drug with potassium salts, potassium-sparing diuretics (spironolactone, triamterene, eplerenone, amiloride), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs, heparins (low molecular weight or unfractionated), cyclosporine, tacrolimus and trimethoprim increases the risk of hyperkalemia.
    • ⓘ The possibility of hypotensive effects when using enalapril can be minimized by stopping the diuretic or increasing salt intake before starting treatment with enalapril.
    • ⓘ Concomitant use of ACE inhibitors with angiotensin II receptor antagonists.
    • ⓘ (ARA II) is contraindicated in patients with diabetic nephropathy and is not recommended in other patients.
    • ⓘ Concomitant use of enalapril with potassium-sparing diuretics (such as spironolactone, eplerenone, triamterene, amiloride), potassium preparations, potassium-containing salt substitutes and other drugs capable of increasing serum potassium content (including angiotensin II receptor antagonists, heparin, tacrolimus, cyclosporine; drugs containing co‑trimoxazole [trimethoprim + sulfamethoxazole]) can lead to a significant increase in the potassium content in blood plasma.
    • ⓘ Other antihypertensive drugs.
    • ⓘ When using enalapril simultaneously with other antihypertensive agents, especially with diuretics, an increased antihypertensive effect may be observed.
    • ⓘ NSAIDs, including selective COX‑2 inhibitors and acetylsalicylic acid in doses of 3 g/day and above, can reduce the antihypertensive effect of diuretics and other antihypertensive agents.
    • ⓘ As a result, the antihypertensive effect of ARA II antagonists or ACE inhibitors may be weakened when used concomitantly with NSAIDs, including selective COX inhibitors‑2.
    • ⓘ Blood pressure should be carefully monitored and, if necessary, the dose of antihypertensive drugs should be adjusted.
    • ⓘ Diuretics (loop and thiazide) can cause a decrease in BCC and thus increase the risk of a pronounced decrease in blood pressure during treatment with the drug.
    • ⓘ If it is necessary to continue taking a diuretic, careful medical monitoring should be provided after taking the initial dose for at least 2 hours and one additional hour before blood pressure stabilizes.
    • ⓘ Enalapril reduces potassium loss caused by thiazide diuretics.
    • ⓘ The use of potassium-sparing diuretics in high doses can lead to hypovolemia (due to a decrease in BCC), and the addition of enalapril to therapy leads to a marked decrease in blood pressure.
    • ⓘ With the simultaneous use of enalapril with potassium-sparing (thiazide or 'loop') diuretics, hypokalemia caused by the action of diuretics, as a rule.
  • No interactions
    • ⓘ It is compatible with beta-blockers, diuretics, ACE inhibitors.
  • Positive interactions
    • ⓘ Concomitant use with other antihypertensive agents may enhance the antihypertensive effect of enalapril.
    • ⓘ The antihypertensive effect of the drug may be potentiated when used simultaneously with other drugs with a similar effect, such as diuretics, beta-, alpha-blockers, etc.; In addition, the following effects may be observed when used together.
    • ⓘ Enhances the effect of curare-like muscle relaxants and antihypertensive drugs (in pm guanethidine, methyldopa, beta-blockers, vasodilators, BCC, MAO inhibitors).
    • ⓘ The antihypertensive effect of enalapril is enhanced by drugs that cause the release of renin (for example, diuretics).
  • Unclear interactions
    • ⓘ Diuretics and ACE inhibitors.
    • ⓘ Lercanidipine can be used simultaneously with diuretics and ACE inhibitors.
    • ⓘ Diuretics.
    • ⓘ Potassium-sparing (thiazide and 'loop') diuretics.

Decoding the colors of interactions and contraindications

Dangerous	—	a pronounced negative interaction or contraindication.
Negative	—	negative interaction or side effect that may reduce effectiveness.
Positive	—	the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication.
No	—	the drugs do NOT interact, which is separately indicated in the instructions.
Unclear	—	the system failed to pre-assess the danger.

Video instruction

▶

Look at ▶Youtube

Additional information

• Kiberis checks interactions and evaluates drug compatibility for free online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
• Why do I need to
  • Avoid dangerous prescriptions for your patients.
  • Check the contraindications.
  • Evaluate the safety of therapy in the treatment of children.
  • See the compatibility of drugs with alcohol (enter it as a drug).
  • Point the doctor to the found interaction - you may need to adjust the therapy.
  • Do you need an API for interactions/drug analogues for your project? Write to us.
• The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
• The article is written: artificial intelligence Kiberis
• Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
• Total analyzed: 170,027,037 possible combinations of drugs and their components were found 412,563 interacting combinations.
• Medicine section: Standard evidence-based medicine
• The date of the last update of the interaction database: 2026-01-01

Category - medicine